Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

Adult Vaccine Market Adult Vaccine Market Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Adult Vaccine Market Report, ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

Vaccine-preventable respiratory diseases like influenza and ... the dynamism in trade in biotech products including vaccines has also been realized. Given that the governments in Asia Pacific ...

GSK royalties are a major revenue source, but declining sales due to competition from newer products may impact future earnings. Innoviva's financial health is at risk due to its reliance on ...

Moderna Chief Financial Officer James Mock said next year's forecast reflects the uncertainty of the COVID and respiratory ...

Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned to replace ageing blockbuster Advair/Seretide not performing in the field.

A good performance by its HIV business, as well as respiratory syncytial ... starting in the US. Products containing the drug, sold by GSK’s majority-owned ViiV Healthcare unit, contributed ...